Table: Anges -2017 group forecast
Jan 22 (Reuters) -
Anges, Inc.
CONSOLIDATED EARNINGS ESTIMATES
(in billions of yen unless specified)
Full Year to Full Year to
Dec 31, 2017 Dec 31, 2017
LATEST PREVIOUS
FORECAST FORECAST
Sales 360 mln 360 mln
Operating loss 3.30 loss 3.40
Recurring loss 3.30 loss 3.40
Net loss 3.76 loss 3.40
EPS loss 49.32 yen loss 44.60 yen
NOTE - Anges, Inc..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4563.T
((Tokyo Headline News Desk +813 6441 1812))
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001